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Abstract
Background: Pseudomonas aeruginosa is responsible for numerous bloodstream infections associated with severe
adverse outcomes in case of inappropriate initial antimicrobial therapy. The present study was aimed to develop a
novel quantitative PCR (qPCR) assay, using ecfX as the specific target gene, for the rapid and accurate identification
of P. aeruginosa from positive blood cultures (BCs).
Methods: Over the period August 2008 to June 2009, 100 BC bottles positive for gram-negative bacilli were tested
in order to evaluate performances of the qPCR technique with conventional methods as gold standard (i.e. culture
and phenotypic identification).
Results: Thirty-three strains of P. aeruginosa, 53 strains of Enterobactericaeae, nine strains of Stenotrophomonas
maltophilia and two other gram-negative species were isolated while 3 BCs were polymicrobial including one
mixture containing P. aeruginosa. All P. aeruginosa clinical isolates were detected by qPCR except a single strain in
mixed culture. Performances of the qPCR technique were: specificity, 100%; positive predictive value, 100%;
negative predictive value, 98.5%; and sensitivity, 97%.
Conclusions: This reliable technique may offer a rapid (<1.5 h) tool that would help clinicians to initiate an
appropriate treatment earlier. Further investigations are needed to assess the clinical benefit of this novel strategy
as compared to phenotypic methods.
Background
Pseudomonas aeruginosa is a major human opportunis-
tic pathogen responsible for numerous nosocomial
infections, especially within intensive care units [1]. In
US hospital settings, P. aeruginosa is the seventh (i.e.
4.3%) most frequently isolated pathogen from the blood-
stream, with a crude mortality exceeding 25% [2].
Although rarely responsible for community-acquired
infections, P. aeruginosa represents 6.8% of bacteremia
caused by gram-negative rods [3]. Since P. aeruginosa
bacteremia is clinically indistinguishable from other
gram-negative bacterial bloodstream infections, it has
been demonstrated that an inappropriate initial antimi-
crobial therapy was associated with severe adverse out-
comes [4-6].
Because standard phenotypic methods are time consum-
ing and most have inherent limitations, molecular techni-
ques have shown to be a rapid and reliable approach for
the identification of bacterial pathogens [7]. Therefore,
several PCR-based methods have already been described
to identify P. aeruginosa, especially in respiratory samples
from cystic fibrosis patients. Different molecular targets
have been employed such as 16 S rRNA, algD, oprI, oprL,
toxA, gyrB,a n decfX genes [8-13]. Since false-positive
results (with 16 S rRNA and oprI genes) as well as false-
negative results (with algD and toxA genes) have been
reported, the ecfX gene is a suitable target for species-
specific identification of P. aeruginosa isolates [11,13].
While identification of P. aeruginosa from a positive
blood culture (BC) takes at least 24 h using conven-
tional techniques, molecular identification directly from
positive BCs could be an interesting alternative leading
to a rapid and accurate species-level identification with
subsequent adequate empirical treatment. However,
PCR detection of P. aeruginosa from positive BCs has
* Correspondence: cattoir-v@chu-caen.fr
1Laboratoire de Bactériologie-Virologie-Hygiène, Hôpital Henri Mondor,
Assistance Publique-Hôpitaux de Paris, Créteil, France
Full list of author information is available at the end of the article
Cattoir et al. Annals of Clinical Microbiology and Antimicrobials 2010, 9:21
http://www.ann-clinmicrob.com/content/9/1/21
© 2010 Cattoir et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.been poorly investigated [14,15], and the authors used
oprI and oprL as target genes, described previously as
non-100% specific [8,11].
In this study, we have developed a novel quantitative
PCR (qPCR) assay, using ecfX as the specific target gene,
for the rapid and accurate identification of P. aeruginosa
from positive BCs
Methods
Clinical specimens and phenotypic identification
From August 2008 to June 2009, a total of 100 positive
BCs from 100 inpatients were included. For each
patient, a pair of aerobic (BacT/ALERT FA) and anaero-
bic (BacT/ALERT FN) bottles was taken, then incubated
in the BacT/ALERT automated continuous monitoring
system (bioMérieux, Marcy-l’Etoile, France). The distri-
bution of positive BCs by bottle type was as follows: 87
aerobic (87%) and 13 (13%) anaerobic. All these BCs
showed gram-negative rods at the direct examination,
a n dm o s to ft h e mp r e s e n t e daG r a m - s t a i n i n ga n d / o ra
motility compatible with those of the species P. aerugi-
nosa. Positive bottles were inoculated aerobically and
anaerobically at 37°C for 24-48 h onto trypticase-soy
agar, Drigalski agar, 5% horse blood agar and chocolate
agar plates, and the concentration of bacteria was deter-
mined by quantitative culture (10-fold serial dilutions
from 10
-1 to 10
-10). Strains were identified by colony
morphology, oxidase reaction, and results of the API 20
E system (bioMérieux).
DNA extraction
From a 0.5-ml aliquot of blood, template DNA was pre-
pared by using a simple and rapid boiling procedure, taking
less than 20 min [16,17]. Briefly, the aliquot was centri-
fuged at 850 × g for 2 min to remove the charcoal. The
supernatant was centrifuged at 11,500 × g for 5 min. The
resulting pellet was resuspended in 200 μl of a lysis buffer
containing 1% Triton X-100, 0.5% Tween 20, 10 mM Tris-
Hcl (pH 8.0), and 1 mM EDTA and incubated at 100°C for
10 min. After centrifugation for 2 min at 850 × g, the
supernatant was directly used for PCR.
Quantitative PCR
The qPCR assay was performed with the LightCycler v.2.0
instrument (Roche, Meylan, France). Oligonucleotide
primers and fluorescent-labeled hybridization probes were
designed for amplification and sequence-specific detection
of a 152-bp fragment within the ecfX gene (Table 1). The
amplification mixture consisted of 2 μl of 10× LightCycler
FastStart DNA Master Hybridization Probes mixture
(Roche), 2 mM MgCl2,0 . 5μM each primer, 0.2 μMe a c h
probe, and 5 μl of template DNA in a final volume of 20
μl. A suspension of Tris-EDTA and a DNA extract of P.
aeruginosa ATCC 27853 were used as negative and posi-
tive controls, respectively. Following an initial denatura-
tion at 95°C for 10 min, the 45-cycle amplification profile
consisted of heating a 95°C segment for 10 s, a 50°C seg-
ment for 10 s, and a 72°C segment for 20 s. The presence
of amplified DNA was measured by detection of emitted
fluorescence at 705 nm, and the final result was available
in ~1.5 h. In parallel, PCR inhibition control was per-
formed for all samples in the same run by using a second
reaction tube containing 100 ng of DNA extract from the
positive control.
Limit of detection
A plasmid standard curve was constructed by ligating
t h e1 5 2 - b pP C Rp r o d u c tf r o mP. aeruginosa ATCC
27853 into the commercial plasmid vector, pCR2.1-
TOPO plasmid vector from the TOPO TA Cloning Kit
(Invitrogen, Cergy-Pontoise, France) following the man-
ufacturer’s recommendations to produce plasmid pRT-
ecfX. This plasmid was transformed into competent
TOP10 Escherichia coli cells (Invitrogen), and transfor-
mants were selected on media containing 30 μg/mL
kanamycin. Plasmid DNA was extracted and purified
from one transformant using the HiSpeed Midi Kit
(Qiagen, Valencia, CA) according to the manufacturer’s
instructions, resuspended in elution buffer (Qiagen) and
sequenced to determine the presence of the ecfX insert
and its orientation. Plasmid DNA concentration was
determined by using the NanoDrop ND-1000 spectro-
photometer (Thermo Scientific, Illkirch, France), and
the plasmid DNA reference material was then serially
diluted to obtain 10 to 10
10 plasmid genome equivalents
for standard curve analysis. Quantitative analysis was
carried out with the LightCycler software version 3.5
(Roche). The ratio of signals measured at 705 nm/sig-
nals measured at 530 nm was used to calculate the
crossing point values.
Table 1 Oligonucleotide primers and LightCycler hybrizidation probes used in the PCR assay
Oligonucleotides Sequence (5’-3’) Target gene Nucleotide position
ecfX-F TTCCATGGCGAGTTGCT 46-62
ecfX-R CGGGCGATCTGGAAAAGAA 179-197
ecfX-HP-1 GCTGAAATGGCCGGGCC-[FAM] ecfX
b 135-151
ecfX-HP-2 [LC705]-CAATCGGTCGAGCAGCCGC-Ph 154-172
a [FAM], fluorescein; [LC705], LightCycler™-Red 705; Ph, 3’-phosphate.
b Extracytoplasmic function gene (GenBank accession no. DQ996551).
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C u l t u r eo ft h e1 0 0B C si s o l a t e d3 3s t r a i n so fP. aerugi-
nosa (including 2 recovered in anaerobic bottles), 53
strains of Enterobacteriaceae (including 22 Escherchia
coli), 9 strains of Stenotrophomonas maltophilia,2
other gram-negative species, and 3 BCs were polymi-
crobial of which one mixture of Klebsiella pneumoniae
and P. aeruginosa (Table 2). Note that the presence of
PCR inhibition was observed only for two (2%) DNA
preparations. Out of the 95 monomicrobial cultures,
the real-time ecfX PCR assay was 100% sensitive and
100% specific for detecting P. aeruginosa.H o w e v e r ,
the PCR assay could not detect the presence of P. aer-
uginosa in a single polymicrobial culture with K.
pneumoniae.B yp e r f o r m i n gt h eP C Ra s s a yd i r e c t l y
from the P. aeruginosa isolate, we could amplify ecfX,
demonstrating that this problem was not due to an
absence or a sequence variation of the gene. By quan-
titative culture, we found that the concentration of
P. aeruginosa in this BC was very low (20 CFU/ml) as
compared with that of K. pneumoniae (10
8 CFU/ml).
Limit of detection was estimated at 10
2 CFU/ml (Fig.
1 and Fig. 2) leading that the absence of signal by
PCR could be explained by a default of sensitivity in
this peculiar case. Taken into account the 98 BCs with
interpretable results (98%), the qPCR assay showed
100% of specificity and PPV, 98.5% of NPV, and 97%
of sensitivity.
Table 2 ecfX qPCR testing of P. aeruginosa from 98 positive blood culture bottles
Organisms No. of samples detected Total no. of samples
PCR
+ PCR
-
Pseudomonas aeruginosa 33 0 33
Escherichia coli 02 1 2 1
Stenotrophomonas maltophilia 09 9
Klebsiella pneumoniae 08 8
Enterobacter cloacae 07 7
Citrobacter koseri 04 4
Enterobacter aerogenes 03 3
Proteus mirabilis 03 3
Morganella morganii 03 3
Serratia marcescens 01 1
Pantoea spp. 0 1 1
Brevundimonas diminuta 01 1
Bacteroides fragilis 01 1
E. coli + Klebsiella oxytoca
a 01 1
E. cloacae + K. oxytoca
a 01 1
K. pneumoniae + P. aeruginosa
a, b 01 1
a Polymicrobial blood cultures.
b, 20 CFU/ml of P. aeruginosa and 10
8 CFU/ml of K. pneumoniae were recovered by quantitative culture.
Figure 1 qPCR amplification curves of plasmid DNA reference material with 11 external DNA concentrations (from 10
11 to 10 copies/
ml).
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Even if the motility in an aerobic bottle may be a good
predictive value of P. aeruginosa isolation, the observa-
tion of non-motile rods or atypical motility is regularly
observed [18] as well as the growth of this aerobe in
anaerobic bottles (6% in our study) [19]. By comparison
with the new FDA-approved technique (i.e. fluorescence
in situ hybrizidation with peptide nucleic acid probes)
directly used on positive BCs, this novel qPCR method
showed similar performances but appeared faster (1.5 h
vs 2.5 h) [20,21]. Nevertheless, a limit of the qPCR tech-
nique is the potential presence of PCR inhibitors (e.g.
charcoal, haemoglobin) in BC specimens.
The timely and accurate information provided by this
qPCR assay would help clinicians identify P. aeruginosa
bacteremia, and thereby initiate adequate antimicrobial
therapy 18 to 24 h earlier than would be possible with
conventional methods, as previously described for Sta-
phylococcus aureus [16,17] and K. pneumoniae [22].
However, as opposed to S. aureus and methicillin resis-
tance, it is difficult to predict an useful antibiotic sus-
ceptibility profile of P. aeruginosa by molecular
techniques even if it is possible to detect several resis-
tance genes such as emerging carbapenemase genes [7].
Indeed, the choice of antibiotic treatment has to con-
sider national and local epidemiology since multidrug
resistant P. aeruginosa isolates are increasingly reported
worldwide [23]. Therefore, in order to minimize the risk
of inappropriate treatment, the use of combination anti-
microbial therapy, until susceptibility results become
known, may be preferable in certain situations [5,6].
Conclusions
As a conclusion, we developed a promising qPCR tech-
nique that offers a fast (<1.5 h) tool with high sensitivity
and specificity for the identification of P. aeruginosa
from positive BCs. Further investigations will be perform
to evaluate the clinical impact of this novel strategy as
compared to conventional methods.
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